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Aleem Mirza, BA, James Pavela, BA, Jean M. Panneton, MD, and Marc H. Glickman, MD, Norfolk, Va
Objective: The Hemodialysis Reliable Outﬂow (HeRO) graft is becoming a recognized alternative to lower extremity
arteriovenous grafts (LEAVGs) as an option for patients who have exhausted traditional upper extremity access; however,
which should be applied preferentially is unclear.
Methods: A retrospective review of LEAVG and HeRO implants from January 2004 to August 2010 was performed.
Patient demographics, medical history, procedural data, and outcomes were evaluated.
Results: Within the time periods, 60 HeROs were placed in 59 patients and 22 LEAVGs were placed in 21 patients.
Demographics were similar between the two groups for many factors; however, the patients who underwent HeRO
placement had signiﬁcantly higher body mass index compared with the LEAVG group. Mean follow-up was 13.9 months
for the HeRO group and 11.9 months for the LEAVG group. The HeRO patients underwent a mean of 6.3 previous
tunneled dialysis catheter insertions and 3.1 previous AVG/arteriovenous ﬁstula placements. The LEAVG patients
underwent placement of a mean of 4.1 previous tunneled dialysis catheters and 2.6 previous AVG/arteriovenous ﬁstulas.
The principal difference was the number of interventions to maintain patency, which was 2.21 per year in the HeRO
group and 1.17 per year in the AVG group (P [ .003) Secondary patency at 6 months was 77% for the HeRO patients
and 83% for the LEAVG patients (P[ .14). The HeRO and LEAVG groups had no difference in infection rate per 1000
days (0.61 vs 0.71; P [ .77) or mortality rate (22% vs 19% respectively; P [ .22) at 6 months.
Conclusions: In access challenged patients, LEAVG and HeRO offer similar rates of secondary patency, infection, and
all-cause mortality. The LEAVG required fewer interventions to maintain patency, and the HeRO maintains the beneﬁt
of utilizing the upper extremity site of venous drainage. In our practice, we prefer the HeRO to LEAVG, especially in
patients with peripheral arterial disease and in the obese population, because it preserves lower extremity access
options. (J Vasc Surg 2013;57:776-83.)Central venous stenosis and central vein occlusion have
become pandemic in the renal dialysis population. For the
more than 350,000 patients in the United States who
depend on hemodialysis (HD), >70% start dialysis with
a catheter and 18% are chronically dependent on catheters
for access. These catheters are fraught with complications
and have been associated with an increased need for
replacement, infection of the access site, and a 1.6 times
increase in sepsis than in patients who are dialyzed through
an arteriovenous ﬁstula or graft.1 The risk is clearly tied to
the catheters, as it has been shown that removal of catheter
dependency can reduce the relative risk of mortality from
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://dx.doi.org/10.1016/j.jvs.2012.09.040The Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines provide an algorithm for placement
of various ﬁstulas and grafts, but it does not provide deﬁni-
tive instructions for patients with central venous obstruction
(CVO). These guidelines support “chest wall” or “neck-
lace” prosthetic graft or lower extremity ﬁstula or graft”;
however, the guidelines also report that “all upper-arm sites
should be exhausted” before catheter dependence.3 The
Society of Vascular Surgery has also made recommendations
regarding vascular access strategies but has not solidiﬁed an
algorithm for the management of patients with CVO.4
Although catheter dialysis has been shown to be subop-
timal, no comparison to date has determined the next best
alternative in patients with CVO. The options explored in
this study are the Hemodialysis Reliable Outﬂow (HeRO)
graft (Hemosphere Inc, Minneapolis, Minn) and the lower
extremity arteriovenous graft (LEAVG).
The HeRO vascular access device was developed for use
in maintaining upper extremity vascular access for HD
patients who have CVO. Katzman et al5 reported that the
HeROdevice had function and patency rates similar to those
of conventional AVGs but was suitable for patients with
impaired venous outﬂow that would preclude upper
extremity subcutaneous vascular access. Long-term data
on the HeRO device are scant, and its role as an option for
long-term dialysis has not been thoroughly described.
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with impaired upper extremity venous drainage. The
LEAVG has been demonstrated to carry a risk of infection
(9%-41%) and ipsilateral limb ischemia (9%), but it is still in
widespread use.6,7 Even with these reported risks, this type
of access is chosen for many patients due to less morbidity
and mortality during access creation compared with other
exotic types of hemoaccess, including axillary–axillary arte-
riovenous straight access (necklace graft),8 superﬁcial
femoral vein transposition,9 and accesses that require
body cavity incisions, such as an axillary artery to right atrial
graft.10
METHODS
Device description. The HeRO device has been clas-
siﬁed by the United States Food and Drug Administration
as a graft and has been commercially available since April
2008. The HeRO, when constructed, consists of a standard
6-mm expanded polytetraﬂuoroethylene (ePTFE) graft,
which is attached to a 5-mm nitinol-reinforced silicone
outﬂow component. An anastomosis is created between
the ePTFE arterial component and an arterial inﬂow
source, either to the brachial or axillary artery. The outﬂow
component is placed into a central vein and does not rely
on a patent extremity outﬂow venous tract. Using endo-
vascular techniques, the outﬂow component can even be
placed across occluded venous segments to a patent central
vein (eg, occluded innominate vein).
The LEAVGs in this study were placed in a loop
(femoral artery to femoral vein) or straight (popliteal artery
to femoral vein) conﬁguration after a preoperative workup
to exclude signiﬁcant peripheral arterial disease of the lower
extremity. A combination of 6-mm straight and tapered
ePTFE as well as 6-mm bovine mesenteric vein (BMV)
were used as conduits at the surgeon’s discretion.
Study design. A retrospective review of LEAVG and
HeRO grafts implanted within a single health network
from January 1, 2004, to August 31, 2010, was performed.
The health network was involved in premarket testing of
the HeRO; however, all patients in this study had the
HeRO placed after commercial release of the device.
Patients were identiﬁed by current procedural terminology
codes for HD graft placement. Exclusion criteria included
patients younger than 18 years or older than 89 years at
the time of access procedure. Patient charts were reviewed
for demographics and preoperative comorbidities. At the
time of index access insertion, the technique of insertion
was recorded as well as any adjunctive maneuvers necessary
for successful implantation. After insertion, the charts were
examined for procedures performed on the access at one of
the medical center sites or the outpatient endovascular
center. Follow-up was recorded until July 31, 2011, by
search of the electronic medical record, which is used for
hospital and ofﬁce-based encounters.
The access modality was selected by the operating
surgeon, who generally adhered to the KDOQI guidelines
as an access strategy. As such, LEAVG and HeRO were
only used as options after traditional ﬁstula and graftoptions were exhausted. All of the surgeons had extensive
experience in percutaneous and open techniques for treat-
ment of central venous stenosis or occlusion; therefore, it
was assumed that every reasonable effort was made to avoid
nontraditional access. Often, treatment of a central venous
occlusion with angioplasty resulted in a functional access,
and an alternate modality was not necessary. Central veno-
grams were obtained both to attempt to treat failing upper
extremity access and to plan subsequent hemoaccess.
Primary outcomes were length of time that the grafts
were capable of providing access for HD or secondary
patency. The need for intervention performed throughout
the life of the graft was also analyzed and compared as
a ratio to the length of time the graft maintained secondary
patency. Secondary outcomes were morbidity related to
the device insertion process, all-cause mortality, and device
infection. Patency deﬁnition was based on standardized
nomenclature as previously outlined.11 Graft infections
were identiﬁed as need for treatment with excision of
a portion or the entire graft at the discretion of the oper-
ating surgeon.
Prior to data collections, the Institutional Review
Board approved study design and scientiﬁc method. Statis-
tical analysis was performed to compare the two groups
using two-sample Wilcoxon test, the Fisher exact test,
and Poisson regression. Kaplan-Meier survival curves
were compared with the log-rank test. Dotted lines were
used to represent the time of the standard error exceeding
10% of the mean. P < .05 was considered statistically signif-
icant. An independent statistician corroborated the statis-
tical analysis.
RESULTS
During the 6.5 years studied, 22 LEAVGs were placed
in 21 patients, and 60 HeRO grafts were placed in 59
patients. One patient had one HeRO and one LEAVG
placed. In total, 97% (58/60) of the HeROs were placed
in the upper extremity using the brachial artery as inﬂow
and the outﬂow placed centrally. Two HeROs were placed
in the lower extremity in a loop conﬁguration from the
femoral artery directly to the vena cava by a retroperitoneal
exposure.
Of the LEAVGs, 91% (20/22) were placed in a loop
conﬁguration from either the common femoral or the
superﬁcial femoral artery to the common femoral or
femoral vein. The remaining 9% (2/22) were constructed
from the popliteal artery to femoral vein in a straight
conﬁguration. Thirty-two percent (7/22) of grafts were
constructed of BMV (Procol; Hancock Jaffe, Irvine, Calif),
and 68% (15/22) were ePTFE. Of the ePTFE grafts, seven
were 6 mm, ﬁve were a tapered graft, and in three proce-
dures the diameter of the ePTFE could not be determined.
The preoperative clinical characteristics of the patients
prior to access placement are summarized in the Table.
Patients who underwent a HeRO insertion had similar
age, sex, height, and race as patients who received an
LEAVG. Not surprisingly, patients selected to receive
an LEAVG were signiﬁcantly more slender, with a mean
Table. Preoperative clinical characteristics
HeRO graft (N ¼ 59) Thigh AVG (N ¼ 20) P value
Age, mean (SD; range), years 58.2 ([14.2]; range, 26.8-86.0) 53.2 ([17.0]; range, 2.5-79.3) .1854
Male 49.2% (29) 30% (6) .1935
Female 50.9% (30) 70% (14)
Height, mean (SD; range), inches 65.7 ([6.0]; range, 38-77) 65.4 ([3.2]; range, 60-70) (n ¼ 19) .5452
Weight, mean (SD; range), pounds 192.7 ([56.3]; range, 112-451)
(n ¼ 59)
160.4 ([24.9]; range, 128-197)
(n ¼ 19)
.0178
Body mass index, mean (SD; median;
range), kg/m2
32.0 ([10.0]; median, 31.6; range,
19.7-75.0) (n ¼ 57)
26.4 ([4.0]; median, 26.6; range,
18.4-32.4) (n ¼ 19)
.0248
Race .1969
Other 3.4% (2) 10% (2)
Black 88.1% (52) 90% (18)
White 8.5% (5) 0% (0)
History of bacteremia 50.9% (30) 10% (2) .0013
Hypertension 91.5% (54) 95% (19) 1
Congestive heart failure 23.7% (14) 15% (3) .5375
Coronary artery disease/myocardial
infarction
33.9% (20) 20% (4) .2771
Cerebrovascular disease/cerebrovascular
accident
18.6% (11) 25% (5) .5346
Chronic obstructive pulmonary disease 13.6% (8) 10% (2) 1
Hyperlipidemia/cholesterolemia 39.0% (23) 15% (3) .0577
Diabetes .0788
None 39.0% (23) 60% (12)
Type I 44.1% (26) 40% (8)
Type II 17.0% (10) 0% (0)
Current tobacco use 13.6% (8) 15% (3) 1
Depression 17.0% (10) 5% (1) .2732
Deep vein thrombosis 30.5% (18) 20% (4) .5644
AVG, Arteriovenous graft; HeRO, Hemodialysis Reliable Outﬂow; SD, standard deviation.
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for HeRO patients (P ¼ .0178). The mean body mass
index, which is derived from weight but takes into account
height, was signiﬁcantly increased in the HeRO cohort at
32 kg/m2 compared with 26 kg/m2 in the LEAVG group
(P ¼ .0248). The two groups were similar for many comor-
bidities, including hypertension, congestive heart failure,
coronary artery disease, cerebrovascular disease, chronic
obstructive pulmonary disease, hyperlipidemia, types of
diabetes, depression. and history of deep vein thrombosis.
A history of positive blood culture was documented in
51% of patients before receiving a HeRO compared with
10% of patients who received an LEAVG (P ¼ .0013).
Patients had undergone multiple previous HD access
procedures before the index event. The mean number
(standard deviation [SD]) of previous AVGs in the
HeRO group was 1.8 (SD, 1.3; median, 2.0; range, 0-5)
and 2.1 ([1.3]; median, 1.5; range, 1-4) in the LEAVG
group (P ¼ .51). The mean arteriovenous ﬁstula creation
in the HeRO group was 1.3 ([0.9]; median, 1.0; range,
0-4) and in the LEAVG group was 0.5 ([0.5]; median,
0.5; range, 0-1; P ¼ .02). Catheters were a large part of
the history of these patients, with the HeRO group having
received a mean of 6.3 ([5.0]; median, 5.0; range, 1-27)
and the LEAVG group having received a mean of 4.1
([3.3]; median, 3.0; range, 0-11; P ¼ .09).
The mean length of time from insertion to either loss of
secondary patency or completion of study was 11.8 months(range, 0.1-59.5 months) for the LEAVG group and
13.9 months (range, 0-37.5 months) for the HeRO group
(P ¼ .94). For determining all-cause mortality, follow-up
concluded at date of death or July 31, 2011, if the patient
was still alive. There was an increased incidence in the
number of procedures necessary to maintain patency in
the HeRO group compared with the LEAVG group. Each
HeRO required a mean of 2.21 interventions per patient
per year compared with 1.17 interventions per patient per
year for the LEAVG group (P ¼ .003).
Of the 40 HeROs that underwent reintervention, 37 of
the ﬁrst procedures (93%) were a thrombectomy. Of the
others, two (5%) were excised for infection and one (2%)
for treatment of steal, one titanium connector (2%) became
dislodged, and one (2%) failed thrombectomy. Of the eight
LEAVGs that underwent reintervention, ﬁve of the ﬁrst
procedures (63%) were a thrombectomy. All three other
LEAVGs (37%) were excised for infection.
Previous studies of LEAVG have reported an increased
risk of infection; however, compared with the HeRO
devices in this study the infection rates are statistically
similar. The LEAVG became infected at a rate of 0.71
per 1000 days, whereas HeROs became infected at a rate
of 0.61 per 1000 days (P ¼ .77). Overall, 13 of 59 HeROs
(22.0%) and 6 of 20 LEAVGs (30%) became infected over
the study period.
Perioperative complications. Within the HeRO
group, one patient died 3 days after a femoral HeRO
Fig 1. Primary patency. AVG, Arteriovenous graft; HeRO, Hemodialysis Reliable Outﬂow (graft).
Fig 2. Secondary patency. AVG, Arteriovenous graft; HeRO, Hemodialysis Reliable Outﬂow (graft).
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toma. One patient developed a hematoma at the site of
the brachial arterial anastomosis, which caused compres-
sion and thrombosis. This patient underwent a thrombec-
tomy on the ﬁrst postoperative day. A third patient
developed upper extremity steal syndrome following
HeRO insertion and on the ﬁrst postoperative day was
treated with a 4-mm ePTFE interposition at the arterial
anastomosis. The only similar complication of the LEAVG
group was one patient with a steal syndrome; however, this
occurred 2.8 years after insertion and was treated with graft
excision.
Survival analysis. Raw data were inspected, and
survival plots were performed to analyze patency over the
study period. At 12 months, only 15% of HeROs main-
tained primary unassisted patency compared with 51% of
LEAVGs. However, due to the small sample size at 1 year,
these percentages are not reliably accurate. Fig 1 shows
the Kaplan-Meier curve of primary patency, which is trun-
cated very early due to small sample size. The standard error
of the mean exceeds 10% at approximately 20 days for the
LEAVG and 60 days for the HeRO and therefore is not
reliable beyond those points. No meaningful comparison
can be made from these primary patency curves. At
12 months, 57% of HeROs maintained secondary patencycompared with 69% of LEAVGs (P ¼ .14; Fig 2). The
statistical validity of this curve exists through 6 months,
showing patency of 77% for HeRO and 83% for LEAVG.
Kaplan-Meier analysis was also performed for survival
free of device infection and all-cause mortality with grafts
(Figs 3 and 4). At 6 months, 84% of HeRO grafts
and LEAVGs required surgical treatment for infection
(P ¼ .76; Fig 3). All-cause mortality at 12 months was
33% in the HeRO group and 20% in the LEAVG group
(P ¼ .22; Fig 4).
DISCUSSION
This study describes the longest follow-up for the
HeRO device and the only direct comparison with LEAVG
from a single center. The KDOQI guidelines provide
a widely accepted strategy for vascular access in the
majority of the HD population; however, the guidelines
provide no clear algorithm in patients who have exhausted
traditional upper extremity access options. The preferred
“unconventional” access has not been elucidated in the
literature. This study shows in a retrospective manner
that the outcomes of LEAVG and HeRO devices are
similar in terms of length of secondary patency, freedom
from infection, and all-cause mortality; however, HeROs
require more interventions to maintain patency.
Fig 4. Kaplan-Meier curve for survival. AVG, Arteriovenous graft; HeRO, Hemodialysis Reliable Outﬂow (graft).
Fig 3. Survival free of device infection. AVG, Arteriovenous graft; HeRO, Hemodialysis Reliable Outﬂow (graft).
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upper extremity ﬁstula insertion (mean, 1.3 for HeRO;
mean, 0.5 for LEAVG) before requiring an alternate access
option despite the responsible surgeon adhering to
a ﬁstula-ﬁrst access strategy. The most signiﬁcant contrib-
uting to the low ﬁstula rate is likely related to the patency
and quality of the superﬁcial venous system in the arms of
these patients. Patients who progress to an alternative
access modality either have poor venous conduits or have
required dialysis for a length of time that has exhausted
the acceptable options that are available.
Katzman et al5 previously reported on 36 HeRO
devices over a mean of 8.6 months and described an inter-
vention rate of 2.5 per patient per year, which is compa-
rable to the rate of 2.2 per year in this study. Their
article also reports an infection rate of 0.70 per 1000
days, similar to our rate of 0.61 per 1000 days.5 Gage
et al12 reported better outcomes of 164 HeROs inserted
at four centers with mean follow-up of 12.8 months,
with an intervention rate of 1.5 per year and an infection
rate of 0.14 per 1000 days. Those outcomes could not
be duplicated in this study. Additionally, the study reports
a 1-year primary patency of 49% and a 1-year secondary
patency of 91%.12 The Dialysis Access Consortium reportfrom a multicenter prospective study published in the
New England Journal of Medicine could not duplicate
these ﬁndings in 649 AVGs. This study reports primary
patency rate of 23% to 28% at 1 year, and another Dialysis
Access Consortium study reports an AVG secondary
patency rate of 62% to 70%.13,14
Cull et al7 previously reviewed a series of 125 LEAVGs
followed for a mean of 20 months. Their report produced
a life-table analysis that approximates this study’s prediction
for primary patency (34% at 1 year), secondary patency
(68% at 1 year), survival (74% at 1 year), and intervention
rates (1.68 per patient per year) for LEAVG.7
There are similarities and differences that can account
for incongruent data between the previously published
reports on HeRO, LEAVG, and this study. Many of these
reports had a small sample size, which is partially due to the
few number of patients who have undergone HeRO and
LEAVG implantation. To some extent this is because the
HeRO was only released commercially in 2008. In addi-
tion, there is a very small subset of the population that
will require an exotic HD access. The small sample size
in this report is reﬂected in the truncated Kaplan-Meier
curves at the point when the data become statistically
unreliable.
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should not be based purely on patency data. Preserving
options for further access as well as a reduction in catheter
dependency should be strong considerations for most
patients. A HeRO may preserve an upper extremity venous
outﬂow that currently is being stented open with an
indwelling catheter. If the upper extremity venous outﬂow
is utilized, this could preserve the lower extremities for
future dialysis access. A key advantage of the HeRO is
that additional access sites can be used and others preserved
for subsequent access options.
A cost analysis would be helpful in comparing these
two modalities of hemoaccess. The expense of the HeRO
is related not only to the device but also to ﬂuoroscopy
and adjunctive endovascular tools that may be necessary
for insertion. The LEAVG has a range of charges that are
related to the AVG conduit used. The reinterventions are
another expense that needs to be factored into the choice
of access. An in-depth cost analysis is beyond the scope
of this study; however, the cost of treating a catheter-
related bloodstream infection likely would surpass the
cost of both device insertion and maintenance.
There are multiple limitations to this study. The
LEAVG patients may not have had a patent upper
extremity venous outﬂow and therefore may not have
been candidates for an upper extremity HeRO. The
LEAVG patients were selected at the discretion of the
operating surgeon and did not have standard exclusion or
inclusion criteria. Ankle-brachial indexes were not assessed
in all cases, and often the quality of the femoral pulse was
the only arterial examination performed. The two groups
were similar in the factors identiﬁed but only were
controlled as much as possible for a retrospective study.
Patients who received HeROs had a greater mean weight
and body mass index. This is likely due to the surgeon’s
preference for avoiding LEAVG and the accompanying
groin incisions in patients with a large abdominal pannus
for fear of graft infection.
There is some heterogeneity to the HeRO population
because two devices were placed in a femoral conﬁguration.
One patient experienced a mortality related to the proce-
dure; however, the other maintained secondary patency
at last follow-up of approximately 6 months. The other
patient previously had been relying on a tenuous transhe-
patic catheter for access and was believed to be better
served with the femoral HeRO.
Another limitation was the length of the Kaplan-Meir
curves. The validity of the life-table analysis can only extend
until the standard error exceeded 10% of the mean. The
length of this time period was negatively inﬂuenced by
the relatively small sample sizes at the onset and the high
proportion of grafts that lost patency during the study
period. Once the grafts lost patency, they were excluded
from this calculation, which effectively reduced the sample
size at that time point.
The medical record reviewed and hospital system
provided treatment for the vast majority of patients in the
area. Although it is possible that a patient could have seenanother surgeon to care for a complication, it is less likely
considering the complexity of these patients’ operative
course. It is thought that the overwhelming majority of
procedures performed after the index procedures were
captured in the chart review.
The LEAVG group was heterogeneous with regard to
the material used for the conduit. The BMV has been adop-
ted by a portion of the surgeons and accounted for one third
of the grafts implanted. The ePTFE was used for the remain-
ing two thirds of the LEAVGs. The BMV may have a better
patency than ePTFE; however, the groups were too small to
produce any signiﬁcant or meaningful conclusions. This is
clearly an area where further studies are needed.
The rate of reintervention in the HeRO group likely is
related to the “mode of failure” of the HeRO. The most
common failure mode of a traditional AV access is intimal
hyperplasia at the venous anastomosis causing stenosis and
occlusion. Because the HeRO does not rely on a venous
anastomosis, its primary mode of failure cannot be extrap-
olated from graft failures and has yet to be discovered.
When a HeRO experiences thrombosis, it normally can
undergo successful thrombectomy because the venous
outﬂow, the vena cava, usually remains patent.
There are limitations to these data and the analysis due
to the retrospective nature of the study. A prospective,
randomized comparison could yield guidelines for manage-
ment of HD patients with CVO that precludes traditional
upper extremity AV access. Until that information is avail-
able, this analysis could provide guidance for access in these
difﬁcult patients by displaying the results of one health
network’s approach.
CONCLUSIONS
In our experience, the advantage of the HeRO over the
LEAVG resides in the ability to maintain an upper
extremity access site with superior vena cava venous
drainage. The advantage of the LEAVG over the HeRO
is the reduction in the number of interventions necessary
to preserve the access. The HeRO is equal to the LEAVG
in secondary patency, rate of infection, and all-cause
mortality. In our practice, we prefer the HeRO to the
LEAVG, particularly in patients with peripheral arterial
disease and in the obese population, because it preserves
the lower extremities for future access options.
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Submitted Jun 19, 2012; accepted Sep 8, 2012.DISCUSSIONDr Julie Freischlag (Baltimore, Md). This is a retrospective anal-
ysis in a small group of patients. Did you determine whether either of
the groups of patients would have been a candidate for the other
graft? Would the HeRO patients have been qualiﬁed for the LEAVG
graft? Is there a need to do a prospective randomized trial or are you
convinced you know which ones should get which graft?
Dr Samuel N. Steerman. Agreed. There are limitations in
this study due to the retrospective nature. We weren’t able to
determine if the patients would have been an appropriate candidate
for the alternate device in our chart review.
One of the problems is not everyone had preoperative ankle-
brachial indexes to determine suitability for LEAVG. Another
problem is although we were able to identify the weight of the
patient and the body mass index, we were not able to determine
whether a patient was acceptable for a thigh graft from a retrospec-
tive chart review. There are clearly patient factors that cannot be
ascertained from reviewing the record, similar in the way that
you can’t determine if a patient is a good candidate for peritoneal
dialysis by a retrospective chart review.
I think this is a promising study that shows some outcomes,
but a prospective randomized study is indicated to really make
some recommendations moving forward on this issue.
Dr Amy Reed (Hershey, Pa). Some of the challenges I think
with this device is the connector piece and the ﬂow dynamics
that change with that when you go from the graft to the catheter.
There have been a few anecdotal reports and some posters pre-
sented at other meetings about use of clopidogrel with these
patients. So I just wondered if any of the patients have had some
different antiplatelet therapy after placement of the HeRO?
Dr Steerman. Thank you for bringing that up. The HeRO
grafts have been associated with increased patency with the use
of clopidogrel. We were able to ﬁnd a similar association; however,
when we split up the patients who were on antiplatelet and those
who were not, we were not able to have a strong enough power to
show a difference in life-table analysis. The association was repli-
cated in this analysis, and we continue to recommend clopidogrel
after HeRO placement.
Dr Harry Schanzer (New York, NY ). We recently presented
at the VASA meeting our experience with the HeRO device in
a smaller population with end-stage vascular access. All of the
patients had had multiple AV accesses in both upper and lower
extremities and presented with central vein stenosis/occlusion.At 6 months, our primary patency was 36.4% and secondary
patency was 54.5%. At 1 year, the primary patency was 9.1% and
secondary patency was 45.5%. Our conclusion was that in order
to obtain a useful utilization of this device, a very aggressive
approach to maintaining secondary patency was required.
My question to you is: since we know that the patency rates
are so low, is there any point in using from the time of implanta-
tion aggressive anticoagulation therapy with Coumadin?
Dr Steerman. I think that’s an interesting point. We looked at
the patients who were on warfarin and did not ﬁnd an association
with improved patency; however, I do not believe we have power
to make any recommendations based on that. It could be some-
thing that could be looked at in the future, but this study was
not able to draw any signiﬁcant conclusions on anticoagulation
recommendations.
Dr Anil Hingorani (Brooklyn, NY ). Your analysis is very inter-
esting, and you’re raising very important questions for a relatively
new device. My concern, however, is you looked at the primary,
secondary patencies and the complications, but there is no real
cost analysis. I’m concerned that this device may actually be so costly
in terms of the initial placement of the device and then subsequent
reinterventions that it may not be cost effective to use it at all.
Dr Steerman. I can give you some data on that; however, it is
beyond the scope of our paper. The grafts that were implanted in
the thigh range from a cost of $700 to approximately $900 just for
the device. For the HeRO, the device cost is $2300, and that’s
prior to performing any adjunct procedures that are necessary or
factoring in any endovascular balloons used to implant the device
or ﬂuoroscopy costs.
In addition, the increased intervention rate also contributes to
the cost of the HeRO device.
If we are speaking of cost, we must also consider the expense
of a hospitalization due to catheter-related bloodstream infection.
Both of these devices reduce the risk of this expense and the
morbid complications of dialysis catheters.
Dr Christopher Carsten (Greenville, SC). Since my partner,
David Cull, and I presented the original series that you were
kind enough to quote frequently, we’ve transitioned to placing
most of our grafts based off of the mid thigh and avoided the groin
and have had much improved results in regards to infection. Do
you all have any experience placing your grafts off of lower than
the groin crease?
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reported basing the graph off of the superﬁcial femoral artery and
femoral vein; however, the exact location with the thigh could not
be clearly elucidated. We did report several straight grafts that were
placed from the popliteal artery to the femoral vein, which may
avoid a larger groin incision and perhaps decrease infection. I
appreciate your comment; this may be a good option for patients
with a redundant abdominal pannus.
Dr Patrick Mahon (Manchester, NH). Did you look at the
failure mode of your HeRO grafts and connect that to where
the distal HeRO was, whether you were placing it because you
had axillary subclavian occlusion and you had to put it in the
central circulation, or do you have central occlusion in the innom-
inate vein and you had to put it in the heart? And was there prob-
lems with stenosis in the outﬂow tract or just clotting off because
of the long outﬂow tract?Dr Steerman. The patient that is typically selected for HeRO
implantation has venous drainage that isn’t enough to support an
upper extremity access. Whether the central venous obstruction
was subclavian, axillary, or central stenosis wasn’t clearly delineated
in the review. Our preference is to place the device through the
internal jugular vein, and the outﬂow tract really doesn’t depend
on a patent axillary or subclavian vein, it only depends on a patent
vein where the tip of the outﬂow component is positioned. So this
wasn’t delineated in our study.
The failure mode of the HeRO was not found to be due to
stenosis within the outﬂow component. The nitinol reinforcement
of the catheter seemed to protect the device from this complication
in our series. The graft component did develop some areas of in-
graft stenosis in some of the cases where the graft thrombosed.
And in some cases no underlying lesion was found, and we weren’t
able to identify the cause of the thrombosis.
